Le Lézard
Classified in: Covid-19 virus
Subject: Lawsuit

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Royal Caribbean Cruises Ltd. (RCL) Investors


Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Royal Caribbean Cruises Ltd. ("Royal Caribbean" or the "Company") (NYSE: RCL) securities between February 4, 2020 and March 17, 2020, inclusive (the "Class Period"). Royal Caribbean investors have until December 7, 2020 to file a lead plaintiff motion.

If you suffered a loss on your Royal Caribbean investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/royal-caribbean-cruises-ltd/.

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 25, 2020, Royal Caribbean disclosed that the COVID-19 pandemic would adversely impact its earnings by $0.90 per share.

On this news, the Company's share price fell $12.55, or 14%, to close at $77.00 per share on February 27, 2020.

On March 10, 2020, Royal Caribbean withdrew its 2020 financial guidance, increased its revolving credit facility by $550 million, and announced that it would take cost-cutting actions due to the continued spread of COVID-19.

On this news, the Company's share price fell $7.30, or 14%, to close at $44.37 per share on March 11, 2020.

On March 11, 2020, Royal Caribbean's largest competitor, Carnival Corporation, announced a 60-day suspension of all operations, which prompted concerns that Royal Carribean's safety procedures were not as "aggressive" as claimed. At the same time, Royal Caribbean also cancelled two cruises.

On this news, the Company's share price fell $14.10, or 32%, to close at $30.27 per share on March 12, 2020.

On March 18, 2020, Stifel cut its one-year price target on Royal Caribbean from $161 to $40.

On this news, the Company's share price fell $5.33, or 19% to close at $22.33 per share on March 18, 2020.

The complaint alleges that throughout the Class Period, the Defendants made false and/or misleading statements and failed to disclose material adverse facts about the Company's decrease in bookings outside China and its faulty policies and procedures to prevent the circulation of COVID-19 on its cruise ships. Specifically, regarding worldwide bookings, Royal Caribbean made announcements that: (1) misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) falsely assured investors that bookings outside China were strong with no signs of a slowdown; and (3) failed to disclose that the Company was undergoing material declines in bookings globally due to customer concerns over COVID-19.

Additionally, regarding safety procedures, the Company made announcements that: (1) falsely assured investors that it implemented rigorous safety procedures; (2) such procedures were expected to ultimately contain the circulation of COVID-19; and (3) failed to disclose that its cruise ships were following grossly inadequate procedures that would facilitate the circulation of COVID-19 and pose a substantial risk to passengers and crews; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased Royal Caribbean securities during the Class Period, you may move the Court no later than December 7, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


These press releases may also interest you

at 10:20
The "Global Functional Milk Market - Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The global functional milk market was valued at $27.00 billion in 2023 and is expected to reach a value of $41.74 billion...

at 10:15
Jazz PharmaceuticalsBy Liz HendersonLiz Henderson, Sr. Vice President Technical Operations at Jazz Pharmaceuticals discusses pioneering innovation in oncology and the importance of the manufacturing infrastructure to help achieve drug development...

at 10:10
Allied Market Research published a report, titled, "Real Estate Investment Trust Market by Type (Equity REITs, Mortgage REITs, and Hybrid REITs), and Application (Industrial, Commercial, and Residential): Global Opportunity Analysis and Industry...

at 10:05
Mayfair Gold Corp. ("Mayfair" or the "Company") today announced that it has received a shareholder meeting requisition notice pursuant to section 167 of the Business Corporations Act (British Columbia) (the "Requisition") dated March 27, 2024 from...

at 09:50
The "Thailand Construction Equipment Rental Market - Strategic Assessment & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Thailand construction equipment rental market is expected to reach a value of $428.7...

at 09:25
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...



News published on and distributed by: